Must og Ahlbom som har lånt ut?
| TRMED | AHLBOM HOLDING AS | Ut av listen |
|---|---|---|
| TRMED | MUST INVEST AS | Ut av listen |
1 Like
De har bare gått ut av topp 50 listen pga andre har økt etter hva jeg kan se
2 Likes
Thor Medical ASA - Share Capital Increase in Relation to the Private Placement and the Retail Offering is Registered
Vi trenger noen gode nyheter…
Hva skjer egentlig med planene i USA når emisjon ble stoppet??
Emisjon ble vel ikke stoppet. Kun repemien som ble avblåst siden den har tradet under emikurs.
Hør intervju med Philina Lee på Youtube Business of Biotech.
M/s Lee er nå CEO hos Radiopharmacy-selskapet Advancell i Boston, MA.
1 Like
Norwegian Prime Minister Jonas Gahr Støre to Officially Open Thor Medical’s AlphaOne Facility on October 19
3 Likes
Synes vel egentlig dette er mer spennende enn at Støre skal offisielt åpne AlphaOne. Interessant å vite hva samarbeidspartnere ser for seg.
2 Likes
Spennende å se om det kommer noe nyheter ut fra dagens “åpning” .
2 Likes
Thor Medical and Medicines Discovery Catapult Enter Three-Year Supply Agreement to Accelerate Radiopharmaceutical Development in the UK
9 Likes
6 Likes
Etter fusjonen mellom Thor Medical AS og Nordic Nanovector ASA i 2024, havnet alle patentene i et eget elskap som heter Nuclithera AS. Thor Medical ASA har en delingsavtale der de får en % andel av et kommende overskudd om Nuclithera lykkes. Dette uten krav til ny egenkapital. Ganske unikt, og i tillegg til det fremførbart underskudd på ca 3 milliarder som Thor Medical ASA overtok, så er dette en fremtidig asset svært få er klar over at Thor Medical ASA eier.
Nå har Nuclithera lykkes med funding til et omfattende CD37 utviklingsløp basert på det gamlebpatentet.
…
NucliThera Awarded NOK 16 Million in Research Council Funding to Advance Next-Generation CD37-Targeted Cancer Therapy
October 29, 2026
NucliThera AS is pleased to announce that the Research Council of Norway (Forskningsrådet) has approved funding for its Next-Generation CD37 project under the Innovation Project for the Industrial Sector (IPN) programme. The four-year project, with approximately NOK 16 million in public funding, will support the development of a new generation of targeted radionuclide therapies for hematological cancers.
The project focuses on developing novel radioconjugates targeting CD37, a protein expressed on several types of blood cancer cells. By combining humanized antibody-based targeting molecules with lead-212 (²¹²Pb), an alpha-emitting radionuclide, NucliThera aims to develop highly targeted therapies capable of delivering potent radiation directly to malignant cells while limiting exposure to healthy tissues.
Building on NucliThera’s established CD37 antibody platform and previous research, the project will focus on optimizing therapeutic candidates, improving their biological distribution and stability, and evaluating their safety and efficacy in preclinical models.
The project will be conducted in collaboration with Oslo University Hospital, combining NucliThera’s expertise in radiopharmaceutical development with established capabilities in preclinical cancer research. Its objective is to identify and characterize a lead therapeutic candidate and generate the preclinical evidence and manufacturing documentation needed to support future clinical development.
“This funding represents an important milestone for NucliThera and a strong recognition of the scientific and therapeutic potential of our CD37 platform. It allows us to accelerate the development of next-generation radiopharmaceuticals while strengthening our collaboration
with leading Norwegian research institutions,” said Roy Larsen, Chairman of the Board and Chief Technology Officer of NucliThera.
The award further strengthens NucliThera’s research and development portfolio and supports the company’s long-term strategy of advancing innovative targeted radionuclide therapies toward clinical application.
About NucliThera AS: NucliThera is an R&D company developing targeted radionuclide therapies for cancer, including lymphoma and leukaemia. Its research combines therapeutic radionuclides with monoclonal antibodies or small molecules to deliver radiation to cancer cells while limiting damage to surrounding healthy tissue.
NucliThera’s research team is jointly led by Chief Scientific Officer Dr Ada RepettoLlamazares, Chief Technology Officer Dr Roy H. Larsen and Chief Medical Officer Professor
Emeritus Øyvind S. Bruland. Dr Larsen and Professor Bruland’s pioneering work includes the development of Xofigo, an alpha-emitting therapy for bone metastases from prostate cancer.
9 Likes